# HOTUNG INVESTMENT HOLDINGS LIMITED

(Incorporated in Bermuda)

## **PROXY FORM**

Due to the current COVID-19 restriction orders in Singapore and in consideration of the well-being of members, the Company will not be providing for physical attendance at the Annual General Meeting. Accordingly, a member will not be able to attend the Annual General Meeting in person. A member (whether individual or corporate) must appoint the Chairman of the Annual General Meeting as his/her/its proxy to attend, speak and vote on his/her/its behalf at the Annual General Meeting if such member wishes to exercise his/her/its voting rights at the Annual General Meeting.

I/We		
of		

being a member/members of **Hotung Investment Holdings Limited** (the "Company") hereby appoint the Chairman of the Annual General Meeting as my/our proxy to attend, speak and vote or abstain for me/us on my/our behalf at the 2021 annual general meeting of the Company to be streamed by "live" webcast on 16 April 2021 (Friday) at 11:00 a.m. (the "Annual General Meeting") and at any adjournment thereof. The Chairman of the Annual General Meeting is hereby directed to vote for or against or abstain from the resolutions to be proposed at the said Annual General Meeting (the "Resolutions") as hereunder indicated. In the absence of specific directions in respect of a Resolution, the appointment of the Chairman of the Annual General Meeting as proxy for that Resolution will be treated as invalid.

To receive and adopt the Directors' Statement and the audited Financial Statements of the Company for the financial year ended 31 December 2020, together with the Independent Auditors'			
Report thereon.			
To approve the declaration of a first and final dividend for the financial year ended 31 December 2020 of NT\$4.02484 per share.			
To re-elect Ms. Tsui-Hui Huang, retiring by rotation pursuant to Bye-laws 94 and 95 of the Bye- laws of the Company and Rule 720(5) of the listing manual of the Singapore Exchange Securities Trading Limited ("SGX-ST") ("Listing Manual").			
To re-elect Dr. Ng-Chee Tan, retiring by rotation pursuant to Bye-laws 94 and 95 of the Bye-laws of the Company and Rule 720(5) of the Listing Manual.			
To re-elect Mr. Chun-Chen Tsou, retiring by rotation pursuant to Bye-laws 94 and 95 of the Bye-laws of the Company and Rule 720(5) of the Listing Manual.			
To re-elect Mr. Kenichi Shimomoto, retiring pursuant to Bye-law 100 of the Bye-laws of the Company.			
To approve the continued appointment of Dr. Ng-Chee Tan as an independent Director by all shareholders of the Company ("Shareholders"), for purposes of Rule 210(5)(d)(iii)(A) of the Listing Manual (which will take effect from 1 January 2022).			
To approve the continued appointment of Dr. Ng-Chee Tan as an independent Director by Shareholders (excluding directors and the chief executive officer of the Company, and their associates), for purposes of Rule 210(5)(d)(iii)(B) of the Listing Manual (which will take effect from 1 January 2022).			
To approve the continued appointment of Mr. Chang-Pang Chang as an independent Director by all Shareholders, for purposes of Rule 210(5)(d)(iii)(A) of the Listing Manual (which will take effect from 1 January 2022).			
To approve the continued appointment of Mr. Chang-Pang Chang as an independent Director by Shareholders (excluding directors and the chief executive officer of the Company, and their associates), for purposes of Rule 210(5)(d)(iii)(B) of the Listing Manual (which will take effect from 1 January 2022).			
To approve the continued appointment of Dr. Philip N. Pillai as an independent Director by all Shareholders, for purposes of Rule 210(5)(d)(iii)(A) of the Listing Manual (which will take effect from 1 January 2022).			
To approve the continued appointment of Dr. Philip N. Pillai as an independent Director by Shareholders (excluding directors and the chief executive officer of the Company, and their associates), for purposes of Rule 210(5)(d)(iii)(B) of the Listing Manual (which will take effect from 1 January 2022).			
To approve Directors' Fees of NT\$9.2 million for the financial year ended 31 December 2020 to the Directors of the Company.			
To re-appoint KPMG LLP as auditors of the Company and to authorize the Directors of the Company to fix their remuneration.			
To approve the Proposed Share Issue Mandate.			
To approve the Proposed Adoption of Share Buy-back Mandate.			
	To re-elect Ms. Tsui-Hui Huang, retiring by rotation pursuant to Bye-laws 94 and 95 of the Bye- aws of the Company and Rule 720(5) of the listing manual of the Singapore Exchange Securities trading Limited ("SGX-ST") ("Listing Manual").  To re-elect Dr. Ng-Chee Tan, retiring by rotation pursuant to Bye-laws 94 and 95 of the Bye-laws of the Company and Rule 720(5) of the Listing Manual.  To re-elect Mr. Chun-Chen Tsou, retiring by rotation pursuant to Bye-laws 94 and 95 of the Bye- laws of the Company and Rule 720(5) of the Listing Manual.  To re-elect Mr. Kenichi Shimomoto, retiring pursuant to Bye-laws 94 and 95 of the Bye- laws of the Company and Rule 720(5) of the Listing Manual.  To re-elect Mr. Kenichi Shimomoto, retiring pursuant to Bye-law 100 of the Bye-laws of the Company.  To approve the continued appointment of Dr. Ng-Chee Tan as an independent Director by all shareholders of the Company ("Shareholders"), for purposes of Rule 210(5)(d)(iii)(A) of the Listing Manual (which will take effect from 1 January 2022).  To approve the continued appointment of Dr. Ng-Chee Tan as an independent Director by shareholders (excluding directors and the chief executive officer of the Company, and their sissociates), for purposes of Rule 210(5)(d)(iii)(B) of the Listing Manual (which will take effect from 1 January 2022).  To approve the continued appointment of Mr. Chang-Pang Chang as an independent Director by shareholders, for purposes of Rule 210(5)(d)(iii)(A) of the Listing Manual (which will take effect from 1 January 2022).  To approve the continued appointment of Mr. Chang-Pang Chang as an independent Director by shareholders, for purposes of Rule 210(5)(d)(iii)(B) of the Listing Manual (which will take effect from 1 January 2022).  To approve the continued appointment of Dr. Philip N. Pillai as an independent Director by shareholders, for purposes of Rule 210(5)(d)(iii)(B) of the Listing Manual (which will take effect from 1 January 2022).  To approve the continued appointment of Dr. Philip N. Pillai as an in	To re-elect Ms. Tsui-Hui Huang, retiring by rotation pursuant to Bye-laws 94 and 95 of the Bye-aws of the Company and Rule 720(5) of the listing manual of the Singapore Exchange Securities Trading Limited ("SGX-ST") ("Listing Manual").  To re-elect Dr. Ng-Chee Tan, retiring by rotation pursuant to Bye-laws 94 and 95 of the Bye-laws of the Company and Rule 720(5) of the Listing Manual.  To re-elect Mr. Chun-Chen Tsou, retiring by rotation pursuant to Bye-laws 94 and 95 of the Bye-laws of the Company and Rule 720(5) of the Listing Manual.  To re-elect Mr. Kenichi Shirmomoto, retiring pursuant to Bye-law 100 of the Bye-laws of the Company.  To approve the continued appointment of Dr. Ng-Chee Tan as an independent Director by all shareholders of the Company ("Shareholders"), for purposes of Rule 210(5)(d)(iii)(A) of the Listing Manual (which will take effect from 1 January 2022).  To approve the continued appointment of Dr. Ng-Chee Tan as an independent Director by Shareholders (excluding directors and the chief executive officer of the Company, and their issociates), for purposes of Rule 210(5)(d)(iii)(B) of the Listing Manual (which will take effect from January 2022).  To approve the continued appointment of Mr. Chang-Pang Chang as an independent Director by all Shareholders, for purposes of Rule 210(5)(d)(iii)(A) of the Listing Manual (which will take effect from 1 January 2022).  To approve the continued appointment of Mr. Chang-Pang Chang as an independent Director by Shareholders (excluding directors and the chief executive officer of the Company, and their issociates), for purposes of Rule 210(5)(d)(iii)(B) of the Listing Manual (which will take effect from January 2022).  To approve the continued appointment of Dr. Philip N. Pillai as an independent Director by Shareholders (excluding directors and the chief executive officer of the Company, and their issociates), for purposes of Rule 210(5)(d)(iii)(B) of the Listing Manual (which will take effect from January 2022).  To approve the continued appointment o	To re-elect Ms. Tsui-Hui Huang, retiring by rotation pursuant to Bye-laws 94 and 95 of the Bye-laws of the Company and Rule 720(5) of the listing manual of the Singapore Exchange Securities (PSG-S-ET) ("Listing Manual").  To re-elect Dr. Ng-Chee Tan, retiring by rotation pursuant to Bye-laws 94 and 95 of the Bye-laws of the Company and Rule 720(5) of the Listing Manual.  To re-elect Mr. Chun-Chen Tsou, retiring by rotation pursuant to Bye-laws 94 and 95 of the Bye-laws of the Company and Rule 720(5) of the Listing Manual.  To re-elect Mr. Kenichi Shimomoto, retiring pursuant to Bye-law 94 and 95 of the Bye-laws of the Company and Rule 720(5) of the Listing Manual.  To approve the continued appointment of Dr. Ng-Chee Tan as an independent Director by all shareholders of the Company ("Shareholders"), for purposes of Rule 210(5)(d)(iii)(A) of the Listing Manual (which will take effect from 1 January 2022).  To approve the continued appointment of Dr. Ng-Chee Tan as an independent Director by Shareholders (excluding directors and the chief executive officer of the Company, and their insociates), for purposes of Rule 210(5)(d)(iii)(B) of the Listing Manual (which will take effect from January 2022).  To approve the continued appointment of Mr. Chang-Pang Chang as an independent Director by all Shareholders, for purposes of Rule 210(5)(d)(iii)(A) of the Listing Manual (which will take effect from January 2022).  To approve the continued appointment of Mr. Chang-Pang Chang as an independent Director by Shareholders (excluding directors and the chief executive officer of the Company, and their issociates), for purposes of Rule 210(5)(d)(iii)(B) of the Listing Manual (which will take effect from January 2022).  To approve the continued appointment of Dr. Philip N. Pillai as an independent Director by Shareholders (excluding directors and the chief executive officer of the Company, and their issociates), for purposes of Rule 210(5)(d)(iii)(B) of the Listing Manual (which will take effect from January 2022).  To approve t

(Please indicate with a cross [X] in the space provided whether you wish your votes to be cast for or against or abstain from the Resolutions as set out in the Notice of Annual General Meeting.)

Dated this day of April 2021.	
No. of shares held :	Signature of member(s) / Common Seal

# Important: Please read notes below

#### Important

- The Annual General Meeting will be streamed by "live" audio-visual webcast and audio only stream on 16 April 2021 at 11:00 a.m. pursuant to the COVID-19 (Temporary Measures) (Alternative Arrangements for Meetings for Companies, Variable Capital Companies, Business Trusts, Unit Trusts and Debenture Holders) Order 2020. Printed copies of the Notice of the Annual General Meeting (the "Notice") have been sent to Shareholders on 1 April 2021, and is also available at the Company's website at URL http://www.hihl.com.sg/eng/hihl/NewsAnnouncements-Announcements.htm. The also be made available at the SGX website at URL the https://www.sgx.com/securities/companyannouncements?value=HOTUNG%20INVESTMENT%20HLDGS%20LTD&type=company.
- 2. Alternative arrangements relating to observing the proceedings of the Annual General Meeting via "live" webcast (including arrangements by which the meeting can be accessed via live audio-visual webcast or live audio only stream), submission of questions to the Chairman of the Annual General Meeting in advance of the Annual General Meeting, addressing of substantial and relevant questions prior to or at the Annual General Meeting and voting by appointing the Chairman of the Annual General Meeting as proxy at the Annual General Meeting, are set out in the Notice.
- 3. Please read the notes below which contain instructions on, *inter alia*, the appointment of the Chairman of the Annual General Meeting as a Shareholder's proxy to attend, speak and vote on his/her/its behalf at the Annual General Meeting.

#### **Notes**

- 1. Due to the current COVID-19 restriction orders in Singapore and in consideration of the well-being of Shareholders, the Company will not be providing for physical attendance at the Annual General Meeting. Accordingly, a Shareholder will not be able to attend the Annual General Meeting in person. A Shareholder (whether individual or corporate) must appoint the Chairman of the Annual General Meeting as his/her/its proxy to attend, speak and vote on his/her/its behalf at the Annual General Meeting if such Shareholder wishes to exercise his/her/its voting rights at the Annual General Meeting. This proxy form Annual General Meeting may be accessed at the Company's website http://www.hihl.com.sg/eng/hihl/NewsAnnouncements-Announcements.htm, and will also be made available on the SGX website at the URI https://www.sgx.com/securities/companyannouncements?value=HOTUNG%20INVESTMENT%20HLDGS%20LTD&type=company.
- The instrument appointing the Chairman of the Annual General Meeting as proxy must be submitted to the Company in the following manner:
  - a. if submitted by post (for Shareholders based outside Singapore), be deposited at the head office of the Company (Attn: The Company Secretary) at 10th Floor, 261 Sung Chiang Road, Taipei, Taiwan, Area Code:104;
  - if submitted by post (for Shareholders based in Singapore), be lodged with the Company's Singapore Share Transfer Agent, M & C Services Private Limited, at 112 Robinson Road #05-01 Singapore 068902; or
  - c. if submitted electronically, via email to the Company's Singapore Share Transfer Agent, M & C Services Private Limited, at <a href="mailto:GPB@mncsingapore.com">GPB@mncsingapore.com</a>,

in either case, not less than 48 hours before the time appointed for the holding of the Annual General Meeting.

A Shareholder who wishes to submit an instrument of proxy must first download, complete and sign the proxy form, before submitting it by post to the address provided above, or before scanning and sending it by email to the email address provided above.

In view of the current COVID-19 situation and the related safe distancing measures which may make it difficult for Shareholders to submit completed proxy forms by post, the Company strongly encourages Shareholders to submit completed proxy forms electronically via email.

3. The instrument appointing the Chairman of the Annual General Meeting as proxy must be under the hand of the appointor or of his attorney duly authorized in writing. Where the instrument appointing the Chairman of the Annual General Meeting as proxy is executed by a corporation, it must be executed under its seal or under the hand of an officer of the corporation or attorney duly authorized in writing. The power of attorney or other authority appointing the attorney or a duly certified copy thereof must (failing previous registration with the Company) be attached to this Proxy Form if it is signed by an attorney.

## PERSONAL DATA PRIVACY:

By submitting an instrument appointing the Chairman of the Annual General Meeting as proxy, the member accepts and agrees to the personal data privacy terms set out in the Notice dated 1 April 2021.

## General

The Company shall be entitled to reject the instrument appointing the Chairman of the Annual General Meeting as proxy if it is incomplete, improperly completed or illegible or where the true intentions of the appointor are not ascertainable from the instructions of the appointor specified in the instrument appointing the Chairman of the Annual General Meeting as proxy.